# OnCo record nct07221474 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07221474/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07221474", "NCT07221474" ;
  schema:name "A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)"@en ;
  schema:alternateName "INTerpath-013"@en ;
  schema:description "A phase 2 trial of Intismeran autogene, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07221474/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07221474> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-12-12" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/> ;
  onco:drugs <https://onco.cc/drugs/intismeran-autogene/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:companies <https://onco.cc/companies/merck/> .